CCCindy H. Chau

Cindy H. Chau

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cindy H. Chau has a total of 260 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Fluorinated Aminopiperidones as Non‐Glutarimide Thalidomide Analogs: Stereodivergent Synthesis and Validation

    by Boštjan Adamlje, Tihomir Tomašič, Christian Steinebach, Sebastian Ebeling, Alexander Herrmann, Marcus D. Hartmann, Jessica L. Horner, Kinjal Bhadresha, Cindy H. Chau, William D. Figg, et al.

    The glutarimide fragment is a key pharmacophore in cereblon‐binding immunomodulatory drugs and proteolysis‐targeting chimeras, yet exploration of non‐glutarimide scaffolds remains limited. Here, we report the design, synthesis, and evaluation of fluorinated aminopiperidones as three‐dimensional, non‐glutarimide thalidomide analogs. By replacing a single glutarimide carbonyl with a stereogenic C*–CF 3 unit, we accessed a previously underexplored chemical space encompassing all regio‐ and diastereomeric variants of 3‐ and 5‐phthalimido‐6‐trifluoromethyl‐2‐piperidones. Stereocontrolled synthetic routes enabled reliable control over relative configurations, and two‐dimensional NMR provided unambiguous structural assignment. Experimental profiling of CF 3 ‐piperidones relative to glutarimides revealed improved aqueous solubility despite increased log D and enhanced membrane interaction characteristics, without substantial changes in plasma protein binding, consistent with sp 3 enrichment and escape‐from‐flatland principles. To assess whether cereblon recognition is retained after carbonyl‐to‐C*–CF 3 replacement, the compounds were evaluated by microscale thermophoresis. No measurable cereblon binding was detected for the fluorinated aminopiperidones. Docking studies, performed to rationalize this lack of affinity, suggested disruption of key cereblon–ligand interactions and unfavorable binding poses following carbonyl‐to‐C*–CF 3 substitution. Several CF 3 ‐piperidones, particularly tetrafluorophthalimide derivatives, exhibited potent anti‐angiogenic activity in vitro and ex vivo, indicating a cereblon‐independent mechanism.

  • Sociodemographic trends in prostate cancer: Insights from the all of Us research program

    by Dhruv G Pillai, Vivian A Guedes, Nicholas G Micheletti, Jessica D Kindrick, Benjamin C Brim, Hyoyoung Choo-Wosoba, Cindy H Chau, William D Figg

    Background: Prostate cancer (PCa) disproportionately affects vulnerable populations. The All of Us Research Program (AoURP) is a database that aims to encapsulate the diversity of the U.S. To explore the utility of this dataset in assessing PCa disparities, we investigated whether treatment usage, disease progression, and genomic research participation vary across sociodemographic factors among AoURP participants with PCa. Methods: We identified AoURP participants with PCa. Genomic research participation in AoURP, treatment usage, time-to-treatment (TTT), and time-to-metastasis (TTM) were assessed by demographics and distance from a National Cancer Institute-designated comprehensive cancer center (NCIDCCC). Multivariable logistic regression and Cox proportional hazards regression were performed to evaluate treatment usage and TTT and TTM, respectively. Results: We observed lower genomic data availability in Black versus White patients (p < 0.001). In multivariable analyses, patients residing >80 miles from an NCIDCCC were less likely to receive ARPIs (OR = 0.30, 95% CI 0.14–0.66, p=.002) and BTAs (OR = 0.46, 95% CI 0.30–0.70, p<.001) but more likely to undergo prostatectomy (OR = 1.97, 95% CI 1.43–2.71, p<.001) than those <40 miles. These patients also initiated treatment faster (HR = 1.54, 95% CI 1.27–1.87, p<.001) and developed metastasis slower (HR = 0.58, 95% CI 0.40–0.86, p=.006). Black patients were less likely to receive radiation (OR = 0.45, 95% CI 0.23–0.88, p=.020), prostatectomy (OR = 0.65, 95% CI 0.44–0.96, p=.028), and BTAs (OR = 0.65, 95% CI 0.45–0.93, p=.018) than White patients. Conclusions: PCa treatment usage, disease progression, and genomic research participation varied between demographic populations. As AoURP matures, additional studies may leverage future data releases to confirm these findings.

  • Open Access

    Hypoxic regulation of chromatin and gene transcription

    by Jessica D. Kindrick, Olivia Lombardi, Silvia Halim, Veronique N. Lafleur, Cindy H. Chau, William D. Figg, Peter J. Ratcliffe, David R. Mole

    Adaptation to reduced levels of oxygen (hypoxia) is an essential feature of eukaryotic life. Within the animal kingdom, cellular responses are orchestrated by the transcription factor HIF (Hypoxia Inducible Factor) which is regulated by specific 2-oxoglutarate-dependent oxygenases. This family of enzymes also includes histone demethylases, and histone methylation has also been observed to increase in hypoxia. Since histone methylation is associated with gene expression, this has raised questions about whether this also contributes to transcriptional regulation in hypoxia. However, to date pangenomic studies have not been normalised in a way that preserves these bulk changes. Using drosophila chromatin spike-in normalisation, we have shown widespread increases in histone H3K4/9/27/36me3 in hypoxia at almost all gene loci that occur irrespective of whether gene expression is increased or reduced. However, methylation of H3K4me3 and H3K36me3 increases most at direct transcriptional targets of HIF and this is abrogated by inactivation of HIF. Taken together this suggests that global H3 trimethylation increases in hypoxia are widespread and not sufficient to predict transcriptional direction, whereas enhanced H3K4me3/H3K36me3 at direct HIF targets appears consequent to HIF binding and transcriptional engagement.


  • Open Access

    Molecular decoupling of lineage identity and morphology in aggressive variant prostate cancer

    by Chennan Li, JuanJuan Yin, Melissa L. Abel, Dana S. Vargas Solivan, Kinjal Bhadresha, Sumeyra Kartal, Samantha Nichols, Kanak Parmar, Joseph Twohig, Tri M. Truong, et al.

    Aggressive variant prostate cancer (AVPC) is a lethal subtype of prostate cancer characterized by its androgen independence, resistance to chemotherapy, and display of neuroendocrine features which can emerge either de novo or via transformation after a prior diagnosis of adenocarcinoma. The poor clinical outcomes in patients with AVPC are associated with its profound molecular heterogeneity. In this study, we analyzed 23 consecutive AVPC cases treated at a dedicated small-cell clinic (2017-2025) using clinicogenomic and transcriptomic profiling. Transformed AVPC exhibited significantly shorter overall survival times than de novo AVPC (11.8 vs 26.0 months, P < 0.001). Integrative genomic analyses identified residual androgen signaling in subsets of cases harboring neuroendocrine lineage programs, highlighting a decoupling of lineage identity and morphology. To facilitate mechanistic and pharmacologic studies, we established NCI-LYM-1, a patient-derived organoid/PDX from an AR-negative, ASCL1+/SYP+ lymph node metastasis, which faithfully recapitulates the donor tumor's molecular and phenotypic features. Short- and long-read whole-genome sequencing combined with optical genome mapping identified biallelic inactivation of PTEN, TP53, RB1 and BRCA2 as potential drivers, demonstrating clonal concordance with circulating tumor DNA from the original patient donor. Pathway and perturbation analyses suggested that NCI-LYM-1 harbored a strong dependency on apoptotic pathways, which was confirmed by in vitro organoid testing with the BCL-2/BCL-xL inhibitor navitoclax (IC50: 0.27 μM) and the MCL-1 inhibitor AZD-5991 (IC50: 0.060 μM). Overall, NCI&-LYM-1 recapitulates the clinical aggressiveness and heterogeneity of AVPC, providing a tractable platform to identify novel precision therapies.


  • Open Access

    Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma

    by Simon Garinet, Karl Semaan, Jiao Li, Ze Zhang, Prathyusha Konda, Ananthan Sadagopan, John Canniff, Noa Phillips, Kelly Klega, Medha Pandey, et al.

    TFE3 translocation renal cell carcinoma (tRCC), an aggressive kidney cancer driven by TFE3 gene fusions, is frequently misdiagnosed owing to morphologic overlap with other kidney cancer subtypes. Conventional liquid biopsy assays that detect tumor DNA via somatic mutations or copy number alterations are unsuitable for tRCC since it often lacks recurrent genetic alterations and because fusion breakpoints are highly variable between patients. We reasoned that epigenomic profiling could more effectively detect tRCC because the driver fusion constitutes an oncogenic transcription factor that alters gene regulation. By defining a TFE3-driven epigenomic signature in tRCC cell lines and detecting it in patient plasma using ChIP-seq, we distinguished tRCC from clear-cell RCC (AUC = 0.86) and samples of individuals without evidence of cancer (AUC = 0.92) at low tumor fractions (<1%). This work establishes a framework for noninvasive epigenomic detection, diagnosis, and monitoring of tRCC, with implications for other mutationally quiet, fusion-driven cancers.


  • Open Access

    Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

    by Juan M. Jiménez-Vacas, Daniel Westaby, Ines Figueiredo, Alexis De Haven Brandon, Ana Padilha, Wei Yuan, George Seed, Denisa Bogdan, Bora Gurel, Claudia Bertan, et al.

    Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease requiring additional therapeutic strategies. MCL1, an anti-apoptotic BCL2 family member, promotes cancer-cell survival, but its role in mCRPC remains poorly understood. Here, we characterise MCL1 in multiple mCRPC biopsy cohorts and patient-derived models, assessing responses to MCL1 inhibition. MCL1 copy number gain (14%–34%) correlates with increased MCL1 expression and worse outcomes. MCL1 inhibition exhibits anti-tumour effects in MCL1-gained mCRPC models. Co-inhibition of MCL1 and AKT induces cancer-specific cell death in PTEN-loss/PI3K-activated models in vitro and in vivo, modulating BAD-BCLXL and BIM-MCL1 interactions, with durable anti-tumour activity in models with AKT inhibitor acquired resistance. Finally, CDK9-mediated MCL1 downregulation combined with AKT inhibition recapitulates these findings, providing further opportunities for clinical translation. These data support early phase clinical trials targeting MCL1, both as monotherapy for MCL1-gained mCRPC, and in combination with AKT inhibition for PTEN-loss/PI3K-activated mCRPC.


  • Open Access

    Figure S4 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

    by Benjamin C. Brim, Andres F. Leon, Erica L. Beatson, Jessica D. Kindrick, Kinjal Bhadresha, Xiaohu Zhang, Giulia C. Napoli, Emily N. Risdon, Keith T. Schmidt, Kelli M. Wilson, et al.

    Figure S4 shows protein level changes after 24 hours of treatment with DMSO, A-1331852, S63845, or the combination of A-1331852 and S63845.

  • Open Access

    Figure 2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

    by Benjamin C. Brim, Andres F. Leon, Erica L. Beatson, Jessica D. Kindrick, Kinjal Bhadresha, Xiaohu Zhang, Giulia C. Napoli, Emily N. Risdon, Keith T. Schmidt, Kelli M. Wilson, et al.

    Co-targeting Mcl-1 and Bcl-xL enhances the inhibitory effect on cell viability. The effect on cell viability of A-1331852 (targeting Bcl-xL) in combination with S63845 (targeting Mcl-1; A–C) and navitoclax (targeting Bcl-xL and Bcl-2) in combination with S63845 (D–F). Cell viability was determined following either 48-hour (22Rv1 and LNCaP-95) or 72-hour treatment (VCaP-CR) by CellTiter-Glo luminescent assay. The data provided represent the mean ± SD from three independent experiments with at least three technical replicates per experiment.

  • Open Access

    Table S2 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

    by Benjamin C. Brim, Andres F. Leon, Erica L. Beatson, Jessica D. Kindrick, Kinjal Bhadresha, Xiaohu Zhang, Giulia C. Napoli, Emily N. Risdon, Keith T. Schmidt, Kelli M. Wilson, et al.

    Table S2 compares the IC50 values of BH3 mimetics as single agents across 2D culture and 3D spheroids.

  • Open Access

    Figure S6 from Direct Co-Targeting of Bcl-xL and Mcl-1 Exhibits Synergistic Effects in AR-V7–Expressing CRPC Models

    by Benjamin C. Brim, Andres F. Leon, Erica L. Beatson, Jessica D. Kindrick, Kinjal Bhadresha, Xiaohu Zhang, Giulia C. Napoli, Emily N. Risdon, Keith T. Schmidt, Kelli M. Wilson, et al.

    Figure S6 shows the effect of treamtent of 3D spheroids with BH3 mimetics as single agents or in combination.